🟠 Moderate Evidence
A selective MET tyrosine kinase inhibitor has demonstrated promising clinical efficacy in patients with MET-amplified gastric or gastroesophageal junction adenocarcinoma, according to findings presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The phase 2 trial results for savolitinib were published in Nature Medicine on June 1, 2026.
Key takeaways
- Savolitinib showed promising clinical efficacy in MET-amplified gastric cancer patients
- The phase 2 trial included both exploratory and pivotal phases
- Results target a specific genetic subgroup with MET amplification
- Findings were presented at the 2026 ASCO Annual Meeting
Study at a Glance
| Source | Nature Medicine |
| Study type | Phase 2 clinical trial |
| Sample size | Not specified in abstract |
| Population | MET-amplified gastric/GEJ adenocarcinoma patients |
| Country | Not specified |
MET Amplification in Gastric Cancer
Targeted therapy approach for specific genetic subgroup
Source: Nature Medicine, 2026 | Georgian Medical Journal News
Targeting MET Amplification in Gastric Malignancies
MET amplification represents a genetic alteration in gastric and gastroesophageal junction adenocarcinomas. Savolitinib, as a selective MET tyrosine kinase inhibitor, specifically targets this molecular pathway according to the Nature Medicine study.
The study design included both exploratory and pivotal phases, allowing researchers to optimize dosing and identify the most appropriate patient population. This approach has become standard for precision oncology trials targeting specific biomarkers.
Clinical Trial Design and Methodology
The phase 2 trial structure represents a comprehensive approach to evaluating savolitinib’s therapeutic potential. According to the FDA’s clinical research guidelines, phase 2 trials focus on determining whether a treatment works while continuing to monitor safety.
The inclusion of patients specifically with MET-amplified tumors reflects the precision medicine approach increasingly adopted in oncology. This biomarker-driven strategy aims to identify patients most likely to benefit from targeted therapy, as outlined in recent clinical research.
ASCO 2026 Presentation Impact
The presentation at the 2026 ASCO Annual Meeting, followed by publication in Nature Medicine, represents a significant milestone for this targeted therapy. ASCO presentations often serve as pivotal moments for advancing cancer treatments toward regulatory approval.
The simultaneous publication in a high-impact medical journal provides the scientific community with detailed methodology and results necessary for clinical implementation.
Implications for Gastric Cancer Treatment
The promising results with savolitinib could represent a significant advance for the subset of patients with MET-amplified tumors, according to the Nature Medicine publication.
Current treatment approaches for advanced gastric cancer typically involve chemotherapy combinations, with targeted agents like trastuzumab reserved for HER2-positive tumors. The addition of savolitinib for MET-amplified cases could expand the precision medicine toolkit for gastric cancer specialists.
Treatment of patients with MET-amplified gastric or gastroesophageal junction adenocarcinoma with savolitinib showed promising clinical efficacy in the phase 2 trial
— Nature Medicine publication, June 2026
What this means
Frequently asked questions
What is MET amplification in gastric cancer?
MET amplification is a genetic alteration where the MET gene is duplicated multiple times, leading to overproduction of MET protein. This alteration can drive tumor growth and spread.
How does savolitinib work?
Savolitinib is a selective MET tyrosine kinase inhibitor that specifically blocks the MET protein’s activity. By targeting this pathway, the drug aims to stop or slow cancer cell growth and division in MET-amplified tumors.
What are the next steps for savolitinib development?
Following promising phase 2 results, the next steps typically involve phase 3 trials comparing savolitinib to standard treatments. Regulatory submissions for approval may follow successful phase 3 results.
The successful development of savolitinib represents part of the broader evolution toward precision oncology in gastric cancer treatment. As biomarker testing becomes more routine and targeted therapies expand, patients with previously limited treatment options may benefit from molecularly-guided approaches. The integration of such targeted agents into clinical practice will require continued collaboration between oncologists, pathologists, and healthcare systems to ensure appropriate patient selection and access.
Source: Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial
Was this article helpful?
Related Coverage
